Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 90,300 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan acquired 90,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average price of C$5.13 per share, for a total transaction of C$463,672.44.

Sime Armoyan also recently made the following trade(s):

• On Monday, September 16th, Sime Armoyan sold 300,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.

Knight Therapeutics Trading Down 0.6 %

Knight Therapeutics stock traded down C$0.03 during mid-day trading on Friday, hitting C$5.19. The company’s stock had a trading volume of 103,432 shares, compared to its average volume of 69,560. The stock has a market cap of C$525.28 million, a price-to-earnings ratio of -26.10, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The business has a 50 day moving average price of C$5.72 and a 200-day moving average price of C$5.74. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics Inc. has a 12 month low of C$5.07 and a 12 month high of C$6.23.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Raymond James lowered their target price on Knight Therapeutics from C$8.00 to C$7.50 in a research report on Thursday. Finally, Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.